PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

類似資料

• Treatment rationale and study design for a phase III, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer
  著者:: Paz-Ares, Luis G, 等
  出版事項: (2010)
• Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup
  著者:: Garrido, Pilar, 等
  出版事項: (2017)
• Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
  著者:: Yang, James Chin-Hsin, 等
  出版事項: (2015)
• Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)
  著者:: ZINNER, RALPH, 等
  出版事項: (2015)
• 65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
  著者:: Schuette, Wolfgang, 等
  出版事項: (2017)